Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceNasdaqAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing sy… Continue reading
BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy CollaborationReutersBRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration. Reuters Staff. 1 Min Read. May 8 (Reuters) – Atara Biotherapeutics Inc: * ATARA BIOTHERAPEUTICS … Continue reading
Genetic Literacy Project |
Synthetic biology’s ‘promise and potential’ capture investor attention
Genetic Literacy Project Synthetic Biology has become the new frontier of genetic engineering, promising to radically change the way we make clothes, fragrances, flavors, biofuels and plastics. Utilizing yeast, algae, microbes and bacteria as tiny manufacturing plants, it may … |
Genetic Literacy Project |
Synthetic biology’s ‘promise and potential’ capture investor attention
Genetic Literacy Project Utilizing yeast, algae, microbes and bacteria as tiny manufacturing plants, it may help us produce meatless meat, non-animal leather and even clean up oil spills. We could find our way to greater sustainability by replacing plastics, metals and wood … |
Positive Newspaper |
Stem Cells in Drug Discovery & Toxicity Screening Conference 2018 (San Diego, CA, United States – October 4th-5th …
GlobeNewswire (press release) Dublin, May 08, 2018 (GLOBE NEWSWIRE) — The “Stem Cells in Drug Discovery & Toxicity Screening 2018″ conference has been added to ResearchAndMarkets.com’s offering. Stem Cells in Drug Discovery, and Toxicity Screening 2018 brings together researchers … Stem Cell Assay Market to Surge at a Robust Pace by 2024Digital Journal Canine Stem Cell Therapy Market to hike at 4.2% CAGR During 2017-2026Technical Progress |
|
Nationwide Children’s gene therapy spinoff raises up to $105M, with option to be acquired
Columbus Business First Sarepta Therapeutics Inc. is investing up to $105 million in the latest gene therapy spinoff from Nationwide Children’s Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promising … |